Alanine Glyoxylate Aminotransferase (AGXT) Antibody

Product Graph
286€ (100 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Alanine Glyoxylate Aminotransferase (AGXT) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx175299
tested applications
WB, IHC, IF/ICC

Description

Alanine Glyoxylate Aminotransferase (AGXT) Antibody is a Rabbit Polyclonal antibody against Alanine Glyoxylate Aminotransferase (AGXT).

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Alanine Glyoxylate Aminotransferase (AGXT)
Host
Rabbit
Reactivity
Human
Recommended Dilution
WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Purification
Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography.
Size 1
100 µl
Size 2
200 µl
Size 3
1 ml
Form
Liquid
Tested Applications
WB, IHC, IF/ICC
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Shipped within 5-7 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P21549
Gene ID
189
Alias
AGXT, AGT1, SPAT
Background
Antibody anti-AGXT
Status
RUO
Note
Concentration: 1 mg/ml -

Descripción

Alanine-glyoxylate aminotransferase (AGXT) is a pyridoxal phosphate-dependent enzyme localized in peroxisomes, where it plays a critical role in detoxifying glyoxylate by converting it into glycine, using alanine as an amino donor. AGXT is central to preventing the overproduction of oxalate, a byproduct of glyoxylate metabolism, which, if accumulated, can form calcium oxalate crystals leading to kidney stones and renal damage. Mutations in the AGXT gene cause primary hyperoxaluria type 1 (PH1), a rare autosomal recessive disorder characterized by excessive oxalate production, kidney stone formation, and systemic oxalosis. AGXT's activity is regulated by intracellular localization and metabolic cues, and therapies targeting AGXT include enzyme replacement therapy and gene therapy to restore glyoxylate metabolism in affected individuals.

Related Products

FNab00224

AGXT antibody

Ver Producto
abx005823

Serine--Pyruvate Aminotransferase (AGXT) Antibody

AGXT Antibody is a Rabbit Polyclonal Antibody against AGXT.

Ver Producto
abx032829

Serine--Pyruvate Aminotransferase (AGXT) Antibody

AGXT is expressed only in the liver and protein is localized mostly in the peroxisomes, where it is involved in glyoxylate detoxification.

Ver Producto